Symptoms of cognitive impairment such as poor concentration, memory loss and difficulty with decision making are prevalent in patients with depression, but currently are not specific targets for treatment. However, patients can continue to demonstrate cognitive impairments even when apparently clinically recovered. Drugs that potentiate serotonin (5-HT) function, such as selective serotonin reuptake inhibitors (SSRIs), are the mainstay of treatment for depression. Nevertheless, our understanding of the effects of SSRIs and other conventional antidepressant therapy on cognitive function in healthy humans and depressed patients remains limited.
Objective:
The purpose of this article is to provide a concise overview for clinicians on the impact of pharmacological manipulation of 5-HT on cognitive function in healthy humans with additional reference to animal models where human data are lacking, particularly regarding specific 5-HT receptor subtype modulation.
Findings:
The most consistent observation following manipulation of serotonin levels in humans is that low extracellular 5-HT levels are associated with impaired memory consolidation. Preclinical data show that agonism and antagonism at specific 5-HT receptors can exert effects in animal models of cognition.
Conclusions:
Larger, consistently designed studies are needed to understand the roles of 5-HT in cognition in healthy and depressed individuals. Efforts to target specific 5-HT receptors to improve cognitive outcomes are warranted.
AkhondzadehSMohammadiNNoroozianM. (2009) Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial. Schizophr Res107: 206–212.
2.
AlbertPRFrancoisBL (2010) Modifying 5-HT1A receptor gene expression as a new target for antidepressant therapy. Front Neurosci4: 35.
3.
AlexopoulosGSRauePAreanP (2003) Problem-solving therapy versus supportive therapy in geriatric major depression with executive dysfunction. Am J Geriatr Psychiatry11: 46–52.
4.
AlhajHASelmanMJervisV. (2012) Effect of low-dose acute tryptophan depletion on the specificity of autobiographical memory in healthy subjects with a family history of depression. Psychopharmacology (Berl)222: 285–292.
5.
AlmeidaSGlahnDCArgyropoulosSV. (2010) Acute citalopram administrationmaydisrupt contextual information processing in healthy males. Eur Psychiatry25: 87–91.
6.
Bang-AndersenBRuhlandTJorgensenM. (2011) Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A novel multimodal compound for the treatment of major depressive disorder. J Med Chem54: 3206–3221.
7.
BonaventurePAluisioLShoblockJ. (2011) Pharmacological blockade of serotonin 5-HT(7) receptor reverses working memory deficits in rats by normalizing cortical glutamate neurotransmission. PLoS One6: e20210.
8.
BorkowskaADrozdzWZiolkowska-KochanM. (2007) Enhancing effect of mirtazapine on cognitive functions associated with prefrontal cortex in patients with recurrent depression. Neuropsychopharmacol Hung9: 131–136.
9.
CastanedaAESuvisaariJMarttunenM. (2008) Cognitive functioning in a population-based sample of young adults with a history of non-psychotic unipolar depressive disorders without psychiatric comorbidity. J Affect Disord110: 36–45.
10.
CegliaIAcconciaSFracassoC. (2004) Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: Role of 5-HT1A receptors. Br J Pharmacol142: 469–478.
11.
ChamberlainSRDelCNDowsonJ. (2007a) Atomoxetine improved response inhibition in adults with attention deficit/ hyperactivity disorder. Biol Psychiatry62: 977–984.
12.
ChamberlainSRMullerUBlackwellAD. (2006) Neurochemical modulation of response inhibition and probabilistic learning in humans. Science311: 861–863.
13.
ChamberlainSRMullerUDeakinJB. (2007b) Lack of deleterious effects of buspirone on cognition in healthy male volunteers. J Psychopharmacol21: 210–215.
14.
ChoSJYookKKimB. (2011) Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry35: 208–211.
15.
CodonyXVelaJMRamirezMJ (2011) 5-HT(6) receptor and cognition. Curr Opin Pharmacol11: 94–100.
16.
de AlmeidaAJMengodG (2007) Quantitative analysis of glutamatergic and GABAergic neurons expressing 5-HT(2A) receptors in human and monkey prefrontal cortex. J Neurochem103: 475–486.
17.
DelgadoPLMillerHLSalomonRM. (1999) Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry46: 212–220.
18.
DepoortereRAuclairALBardinL. (2010) F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists. Eur Neuropsychopharmacol20: 641–654.
19.
DruekeBBaetzJBoeckerM. (2009) Differential effects of escitalopram on attention: A placebo-controlled, double-blind cross-over study. Psychopharmacology (Berl)207: 213–223.
20.
DruekeBBoeckerMSchlaegelS. (2010) Serotonergic modulation of response inhibition and re-engagement? Results of a study in healthy human volunteers. Hum Psychopharmacol25: 472–480.
21.
EversEAvan der VeenFMvan DeursenJA. (2006) The effect of acute tryptophan depletion on the BOLD response during performance monitoring and response inhibition in healthy male volunteers. Psychopharmacology (Berl)187: 200–208.
22.
Garcia-CarboneroRPaz-AresL (2002) Antibiotics and growth factors in the management of fever and neutropenia in cancer patients. Curr Opin Hematol9: 215–221.
23.
HaddadADWilliamsJMMcTavishSF. (2009) Low-dose tryptophan depletion in recovered depressed women induces impairments in autobiographical memory specificity. Psychopharmacology (Berl)207: 499–508.
24.
HarmerCJBhagwagarZCowenPJ. (2002) Acute administration of citalopram facilitates memory consolidation in healthy volunteers. Psychopharmacology (Berl)163: 106–110.
25.
HasbroucqTRihetPBlinO. (1997) Serotonin and human information processing: fluvoxamine can improve reaction time performance. Neurosci Lett229: 204–208.
26.
HasselbalchBJKnorrUHasselbalchSG. (2012) Cognitive deficits in the remitted state of unipolar depressive disorder. Neuropsychology26: 642–651.
27.
HasselbalchBJKnorrUKessingLV (2011) Cognitive impairment in the remitted state of unipolar depressive disorder: A systematic review. J Affect Disord134: 20–31.
28.
HaywardGGoodwinGMCowenPJ. (2005) Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms. Biol Psychiatry57: 517–524.
29.
HermensDFRedoblado HodgeMANaismithSL. (2011) Neuropsychological clustering highlights cognitive differences in young people presenting with depressive symptoms. J Int Neuropsychol Soc17: 267–276.
30.
Herrera-GuzmanIGudayol-FerreEHerrera-AbarcaJE. (2010) Major Depressive Disorder in recovery and neuropsychological functioning: Effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery. J Affect Disord123: 341–350.
31.
Herrera-GuzmanIGudayol-FerreEHerrera-GuzmanD. (2009) Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatr Res43: 855–863.
32.
Herrera-GuzmanIGudayol-FerreELira-MandujanoJ. (2008) Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder. Psychiatry Res160: 72–82.
33.
HodgesHSowinskiPTurnerJJ. (1996) Comparison of the effects of the 5-HT3 receptor antagonists WAY-100579 and ondansetron on spatial learning in the water maze in rats with excitotoxic lesions of the forebrain cholinergic projection system. Psychopharmacology (Berl)125: 146–161.
34.
HuangCQWangZRLiYH. (2011) Cognitive function and risk for depression in old age: A meta-analysis of published literature. Int Psychogeriatr23: 516–525.
35.
JaegerJBernsSUzelacS. (2006) Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res145: 39–48.
36.
JensenNHCremersTISottyF (2010) Therapeutic potential of 5-HT2C receptor ligands. ScientificWorldJournal10: 1870–1885.
37.
KatonaCHansenTOlsenC (2012) A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol27: 215–223.
38.
KerestesRLadouceurCDMedaS. (2012) Abnormal prefrontal activity subserving attentional control of emotion in remitted depressed patients during a working memory task with emotional distracters. Psychol Med42: 29–40.
39.
KingMVMarsdenCAFoneKC (2008) A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol Sci29: 482–492.
40.
LashTLSillimanRAGuadagnoliE. (2000) The effect of less than definitive care on breast carcinoma recurrence and mortality. Cancer89: 1739–1747.
41.
LeeRSHermensDFPorterMA. (2011) A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. J Affect Disord140: 113–1242.
42.
LevkovitzYArnestGMendlovicS. (2005) The effect of ondansetron on memory in schizophrenic patients. Brain Res Bull65: 291–295.
43.
Liem-MoolenaarMRadMZamunerSCohenAF. (2011) Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men. Br J Clin Pharmacol71: 907–916.
44.
MaaloufFTBrentDClarkL. (2011) Neurocognitive impairment in adolescent major depressive disorder: State vs. trait illness markers. J Affect Disord133: 625–632.
45.
MalbergJEEischAJNestlerEJ. (2000) Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci20: 9104–9110.
46.
MannieZNHarmerCJCowenPJ. (2010) A functional magnetic resonance imaging study of verbal working memory in young people at increased familial risk of depression. Biol Psychiatry67: 471–477.
47.
MarchettiEChaillanFADumuisA. (2004) Modulation of memory processes and cellular excitability in the dentate gyrus of freely moving rats by a 5-HT4 receptors partial agonist, and an antagonist. Neuropharmacology47: 1021–1035.
48.
McCallWVDunnAG (2003) Cognitive deficits are associated with functional impairment in severely depressed patients. Psychiatry Res121: 179–184.
49.
McClintockSMHusainMMWisniewskiSR. (2011) Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol31: 180–186.
50.
McDermottLMEbmeierKP (2009) A meta-analysis of depression severity and cognitive function. J Affect Disord119: 1–8.
51.
McKinnonMCYucelKNazarovA. (2009) A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci34: 41–54.
52.
MendelsohnDRiedelWJSambethA (2009) Effects of acute tryptophan depletion on memory, attention and executive functions: A systematic review. Neurosci Biobehav Rev33: 926–952.
53.
MenesesA (2007) Stimulation of 5-HT1A, 5-HT1B, 5-HT2A/2C, 5-HT3 and 5-HT4 receptors or 5-HT uptake inhibition: Short- and long-term memory. Behav Brain Res184: 81–90.
54.
MillanMJAgidYBruneM. (2012) Cognitive dysfunction in psychiatric disorders: Characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov11: 141–168.
55.
NaismithSLLongleyWAScottEM. (2007) Disability in major depression related to self-rated and objectively-measured cognitive deficits: A preliminary study. BMC Psychiatry7: 32.
56.
NathanPJSitaramGStoughC. (2000) Serotonin, noradrenaline and cognitive function: A preliminary investigation of the acute pharmacodynamic effects of a serotonin versus a serotonin and noradrenaline reuptake inhibitor. Behav Pharmacol11: 639–642.
57.
O’HanlonJFRobbeHWVermeerenA. (1998) Venlafaxine’s effects on healthy volunteers’ driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens. J Clin Psychopharmacol18: 212–221.
58.
OlverJSIgnatiadisSMaruffP. (2008) Quetiapine augmentation in depressed patients with partial response to antidepressants. Hum Psychopharmacol23: 653–660.
59.
OrsettiMDellaroleAFerriS. (2003) Acquisition, retention, and recall of memory after injection of RS67333, a 5-HT(4) receptor agonist, into the nucleus basalis magnocellularis of the rat. Learn Mem10: 420–426.
60.
OwnbyRLCroccoEAcevedoA. (2006) Depression and risk for Alzheimer disease: Systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry63: 530–538.
61.
PoirierMFGalinowskiAAmadoI. (2004) Double-blind comparative study of the action of repeated administration of milnacipran versus placebo on cognitive functions in healthy volunteers. Hum Psychopharmacol19: 1–7.
62.
PuigMVGulledgeAT (2011) Serotonin and prefrontal cortex function: Neurons, networks, and circuits. Mol Neurobiol44: 449–464.
63.
RamaekersJGMuntjewerffNDO’HanlonJF (1995) A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br J Clin Pharmacol39: 397–404.
64.
RiedelWJEikmansKHeldensA. (2005) Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment. J Psychopharmacol19: 12–20.
65.
RothBLHanizavarehSMBlumAE (2004) Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl)174: 17–24.
66.
RussoOCachard-ChastelMRiviereC. (2009) Design, synthesis, and biological evaluation of new 5-HT4 receptor agonists: Application as amyloid cascade modulators and potential therapeutic utility in Alzheimer’s disease. J Med Chem52: 2214–2225.
67.
SabbaghMN (2009) Drug development for Alzheimer’s disease: Where are we now and where are we headed?Am J Geriatr Pharmacother7: 167–185.
68.
SantanaNBortolozziASerratsJ. (2004) Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex14: 1100–1109.
69.
SantarelliLSaxeMGrossC. (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science301: 805–809.
70.
SchmittJARamaekersJGKruizingaMJ. (2002) Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. J Psychopharmacol16: 207–214.
71.
SchoningSZwitserloodPEngelienA. (2009) Working-memory fMRI reveals cingulate hyperactivation in euthymic major depression. Hum Brain Mapp30: 2746–2756.
72.
Selva-VeraGBalanza-MartinezVSalazar-FraileJ. (2010) The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia. BMC Psychiatry10: 47.
73.
SiepmannMGrossmannJMuck-WeymannM. (2003) Effects of sertraline on autonomic and cognitive functions in healthy volunteers. Psychopharmacology (Berl)168: 293–298.
74.
SiepmannTMueck-WeymannMOertelR. (2008) The effects of venlafaxine on cognitive functions and quantitative EEG in healthy volunteers. Pharmacopsychiatry41: 146–150.
75.
SiuciakJAChapinDSMcCarthySA. (2007) CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology52: 279–290.
76.
StenbergJHTerevnikovVJoffeM. (2010) Effects of add-on mirtazapine on neurocognition in schizophrenia: A double-blind, randomized, placebo-controlled study. Int J Neuropsychopharmacol13: 433–441.
77.
StenbergJHTerevnikovVJoffeM. (2011) More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry35: 1080–1086.
78.
SumiyoshiTMatsuiMYamashitaI. (2000) Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol20: 386–388.
79.
SumiyoshiTMatsuiMYamashitaI. (2001) The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry49: 861–868.
80.
SumiyoshiTParkSJayathilakeK. (2007) Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: A randomized, double-blind, placebo-controlled study. Schizophr Res95: 158–168.
81.
TakahashiMIwamotoKKawamuraY. (2010) The effects of acute treatment with tandospirone, diazepam, and placebo on driving performance and cognitive function in healthy volunteers. Hum Psychopharmacol25: 260–267.
82.
TerryAVJr.BuccafuscoJJBartoszykGD (2005) Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys. Psychopharmacology (Berl)179: 725–732.
83.
TerryAVJr.BuccafuscoJJJacksonWJ. (1998) Enhanced delayed matching performance in younger and older macaques administered the 5-HT4 receptor agonist, RS 17017. Psychopharmacology (Berl)135: 407–415.
84.
TerryAVJr.BuccafuscoJJPrendergastMA. (1996) The 5-HT3 receptor antagonist, RS-56812, enhances delayed matching performance in monkeys. Neuroreport8: 49–54.
85.
van der VeenFMEversEAvan DeursenJA. (2006) Acute tryptophan depletion reduces activation in the right hippocampus during encoding in an episodic memory task. Neuroimage31: 1188–1196.
86.
WagnerSHelmreichILiebK. (2012) A meta-analysis of executive dysfunctions in unipolar major depressive disorder (MDD) without psychotic symptoms and their changes during antidepressant treatment. Eur Psychiatry27 Supplement1:1.
87.
WalstabJRappoldGNieslerB (2010) 5-HT(3) receptors: Role in disease and target of drugs. Pharmacol Ther128: 146–169.
88.
WarburtonECHarrisonAARobbinsTW. (1997) Contrasting effects of systemic and intracerebral infusions of the 5-HT1A receptor agonist 8-OH-DPAT on spatial short-term working memory in rats. Behav Brain Res84: 247–258.
89.
WestrichLPehrsonAZhongH. (2012) In vitro and in vivo effects for the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int J Psychiatry Clin Pract16: 47.
90.
WingenMKuypersKPRamaekersJG (2007a) The role of 5-HT1a and 5-HT2a receptors in attention and motor control: A mechanistic study in healthy volunteers. Psychopharmacology (Berl)190: 391–400.
91.
WingenMKuypersKPRamaekersJG (2007b) Selective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRI. J Psychopharmacol21: 477–485.
92.
WingenMLangerSRamaekersJG (2006) Verbal memory performance during subchronic challenge with a selective serotonergic and a mixed action antidepressant. Hum Psychopharmacol21: 473–479.
93.
WittorfASickingerSWiedemannG. (2008) Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: A naturalistic 6-month follow-up study. Arch Clin Neuropsychol23: 271–282.
